Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA
December 22, 2010
Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA
Spartan Bioscience has gained a CE IVD Mark for its Spartan RX CYP2C19 point-of-care test to guide antiplatelet treatment. Meanwhile, the firm is planning a US regulatory filing in 2011.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs
August 11, 2010 / Pharmacogenomics Reporter - Spartan Bioscience Building Evidence for Point-of-Care PGx Testing to Guide Antiplatelet Therapy
March 13, 2013 / Pharmacogenomics Reporter - Dx Firms GenMark, Nanosphere, CombiMatrix Attribute Q1 Revenue Growth to Sales Efforts
May 14, 2013 / BioArray News - Cowen & Co. Initiates Coverage of GenMark, Nanosphere with Outperform Ratings
April 22, 2013 / GenomeWeb Daily News - FDA Clears Nanosphere's CYP2C19 Test to Guide Therapeutic Strategy, Not Predict Response
November 14, 2012 / Pharmacogenomics Reporter